Xcell Biosciences, Inc., a developer of innovative technologies and platforms designed to further the research, development, and manufacturing of cell and gene therapies, announced $27.5 million in Series B financing led by Casdin Capital. Also participating in this financing are new investors Dynamk Capital, Formic Ventures, and Labcorp, as well as existing investors HBM Genomics and Viking Global Investors.

Xcellbio is a venture-backed company driven by its mission to enhance the performance and safety of cell and gene-based therapies through the design and development of revolutionary technology platforms. The company's commercial instruments and AI-driven software allow researchers to discover novel insights into immune and tumor biology and enable the translation of these insights at patient scale through the development of its pioneering cell therapy manufacturing platform.